Filing Flows

Filing Flows › Companies › Rapid Micro Biosystems › Cash flow

Rapid Micro Biosystems cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$12.5M in Q2 2026 · −$40.4M over twelve months

Operating cash flow−$12.7M
Capital spending$223K
Free cash flow−$12.5M
Cash conversion cycle243 days

Analysis

In Q2 2026, Rapid Micro Biosystems generated −$12.7M of operating cash flow and spent −$223K on capital projects, leaving free cash flow of −$12.5M. That is $2.4M less than in Q2 2025 (−$10.1M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$40.1M; the largest uses were operating cash flow ($40.1M), capital spending ($336K), net borrowing (+) / repaid (−) ($34K); besides operations, cash came from other financing ($29.1M), other investing ($7.5M); the cash balance fell by $3.6M.

Operating cash flow was −$12.7M against net income of −$12.9M. The largest differences: inventory −$1.8M, stock-based pay +$1.3M, deferred revenue −$1.1M.

Its cash conversion cycle was 243 days (receivables 67 + inventory 242 − payables 65).

Free cash flow

Rapid Micro Biosystems: free cash flow by quarterRapid Micro Biosystems: free cash flow by quarter−$8.8MQ3 2024−$10.0MQ4 2024−$9.4MQ1 2025−$10.1MQ2 2025−$9.1MQ3 2025−$3.3MQ4 2025−$15.5MQ1 2026−$12.5MQ2 2026
Operating cash flow less capital spending.
Rapid Micro Biosystems: operating cash flow against capital spendingRapid Micro Biosystems: operating cash flow against capital spendingOperating cash flowCapital spending−$8.6M$223KQ3 2024−$9.9M$98KQ4 2024−$9.1M$319KQ1 2025−$9.7M$366KQ2 2025−$9.1M$73KQ3 2025−$3.2M$92KQ4 2025−$15.1M$394KQ1 2026−$12.7M−$223KQ2 2026
Latest (Q2 2026): Operating cash flow −$12.7M, Capital spending −$223K.

Capital allocation, year by year

Rapid Micro Biosystems: where the cash came from (up) and went (down), by fiscal yearRapid Micro Biosystems: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$55.0MFY2021: Net borrowing −$26.2MFY2021: Shares issued $165MFY2021: Asset sales $20KFY2021: Capital spending −$3.2M$165MFY2021FY2022: Operating cash flow −$58.5MFY2022: Net borrowing −$33KFY2022: Shares issued $566KFY2022: Capital spending −$6.7M$566KFY2022FY2023: Operating cash flow −$45.1MFY2023: Net borrowing −$37KFY2023: Shares issued $6KFY2023: Capital spending −$1.8M$6KFY2023FY2024: Operating cash flow −$44.2MFY2024: Net borrowing −$35KFY2024: Shares issued $7KFY2024: Capital spending −$1.4M$7KFY2024FY2025: Operating cash flow −$31.1MFY2025: Net borrowing $20.0MFY2025: Shares issued $936KFY2025: Capital spending −$850K$20.9MFY2025
Over these 5 years operating cash flow totalled −$234M; the largest uses were operating cash flow ($234M) and net borrowing ($26.3M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$19.8M
Debt$19.1M
Net cash$627K
Cash runway6 months

Rapid Micro Biosystems is burning cash: its operations consume cash, a free cash flow of −$40.4M a year at the current rate against $19.8M of cash and investments: a runway of about 6 months before any new financing.

Where the cash came from and went

Rapid Micro Biosystems: sources (+) and uses (−) of cash, Q2 2026Rapid Micro Biosystems: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$12.7MOther financing$9.3MOther investing$4.0MCash drawn (+) / kept (−)−$872KCapital spending$223KShares issued$67KNet borrowing (+) / repaid (−)−$9K
Rapid Micro Biosystems: sources (+) and uses (−) of cash, TTM to Q2 2026Rapid Micro Biosystems: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$40.1MOther financing$29.1MOther investing$7.5MCash drawn (+) / kept (−)$3.6MCapital spending−$336KShares issued$251KNet borrowing (+) / repaid (−)−$34KTaxes on employees’ shares−$1K

From profit to cash

Rapid Micro Biosystems: net income to operating cash flow, Q2 2026Rapid Micro Biosystems: net income to operating cash flow, Q2 2026Net income−$12.9MDepreciation & amortization$674KStock-based pay$1.3MOther non-cash$57KReceivables$852KInventory−$1.8MPayables$408KAccrued liabilities−$955KDeferred revenue−$1.1MPrepaid and other assets$400KOperating cash flow−$12.7M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 20266724265243
Q1 20265320752208
Q2 20256626939296
Q1 20257527134312

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$12.7M$223K−$9K$67K−$872K−$12.5M
Q1 2026−$15.1M−$394K−$9K$116K$6.2M−$15.5M
Q4 2025−$3.2M−$92K−$8K$6K−$1.1M−$3.3M
Q3 2025−$9.1M−$73K−$8K$62K−$613K−$9.1M
Q2 2025−$9.7M−$366K−$7K$127K$654K−$10.1M
Q1 2025−$9.1M−$319K−$7K$296K−$2.0M−$9.4M
Q4 2024−$9.9M−$98K−$6K—$5.1M−$10.0M
Q3 2024−$8.6M−$223K−$9K$7K$15.1M−$8.8M

Rapid Micro Biosystems: income statement and cash flow

Rapid Micro Biosystems, Q2 2026: revenue $8.1M (+11% year over year), operating margin -153.0%. The chart follows the revenue to costs, profit and cash.

Rapid Micro Biosystems: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.